Introduction {#s01}
============

With over 170 years of clinical use since the public demonstration of general anesthesia, the molecular mechanisms of general anesthetic drugs are still not fully understood ([@bib16]; [@bib15]). It is widely accepted that general anesthetics alter neuronal signaling by interacting with membrane proteins, in particular ligand-gated ion channels, rather than with the lipid bilayer ([@bib20]). More recent evidence suggests that voltage-gated ion channels, including presynaptic voltage-gated Na^+^ channels (Na~v~), are important targets for anesthetic ethers ([@bib15]; [@bib17]). Several mammalian isoforms of Na~v~, which in neurons drive the upstroke of the action potential and act upstream of neurotransmitter release, are inhibited by the common volatile anesthetic (VA) isoflurane ([@bib42]; [@bib46]; [@bib33]; [@bib18], [@bib19]; for review, see [@bib17]). However, the mechanisms by which VAs such as isoflurane inhibit Na~v~ remain unresolved.

Homologous bacterial voltage-gated Na^+^ channels have emerged as useful structural and functional models for the more complex mammalian Na~v~ ([@bib10]; [@bib37]). The prokaryotic channels are expressed as monomers that form homotetrameric channels (in contrast to the four contiguous pore-forming domains of mammalian Na~v~ α-subunits), making them more amenable to heterologous expression, mutagenesis, and x-ray crystallography ([@bib38], [@bib39]; [@bib31]; [@bib51]; [@bib45]). Prokaryotic Na~v~ lack the fast-inactivation particle found in eukaryotic Na~v~ but exhibit slow inactivation similar to eukaryotic Na~v~ ([@bib26]; [@bib36]; [@bib21]), such that prokaryotic Na~v~ homologues are particularly useful in isolating pharmacological effects on slow inactivation.

NaChBac, the voltage-gated Na^+^ channel from *Bacillus halodurans* ([@bib44]), is modulated by isoflurane ([@bib34]) and sevoflurane ([@bib7]). Isoflurane reduces peak Na^+^ current (*I*~Na~) at more depolarized holding potentials, shifts the steady-state inactivation (SSI) curve in the hyperpolarizing direction, and accelerates apparent inactivation, which was interpreted as preferential binding to an inactivated state ([@bib34]). In contrast, modeling studies have suggested that sevoflurane inhibits NaChBac by slow open channel block with no effect on inactivation kinetics ([@bib7]). Despite these different proposed mechanisms of action, the structurally similar halogenated ethers isoflurane and sevoflurane have similar effects on Na~v~1.4 ([@bib35]). Of interest, molecular dynamics simulations have identified multiple sites of interaction for both isoflurane ([@bib41]) and sevoflurane ([@bib7]) with NaChBac, including the pore cavity and fenestrations, S4--S5 linker, activation gate, and selectivity filter. Recently, binding of isoflurane to NaChBac was identified using ^19^F nuclear magnetic resonance (^19^F NMR; [@bib24]). Strong interactions were found with the S4--S5 linker, an extracellular pore loop, and the base of the selectivity filter, which were postulated as sites involved in channel inhibition. To validate these computational and structural findings and better understand Na~v~ modulation by anesthetic ethers, functional electrophysiological analyses are paramount. Previous functional studies showed that isoflurane accelerates activation ([@bib34]), an effect not addressed in previous computational and structural studies, and it is possible that anesthetic-induced changes in macroscopic inactivation arise indirectly through altered activation ([@bib2]).

We therefore investigated isoflurane effects on the electrophysiological properties of WT NaChBac and NaChBac mutated to alter activation and inactivation. We analyzed our empirical electrophysiological data using a recognized Markov model of NaChBac gating ([@bib26]) to resolve isoflurane effects on discrete gating parameters and better discern its mechanisms of action. Our results indicate that the primary effects of isoflurane on NaChBac gating include enhancement of both forward activation and inactivation rate constants that arise from the reduction of associated free energy barriers, and do not favor slow open channel block.

Materials and methods {#s02}
=====================

NaChBac constructs {#s03}
------------------

WT NaChBac cDNA (from *B. halodurans*) in a modified pTracer expression vector with a GFP-Zeocin site (Invitrogen) was provided by D. Clapham (Harvard University, Boston, MA). NaChBac slow inactivation was modified by introducing two known point mutations in the S6 helix at the so-called gating hinge: G219A accelerates and G229A slows inactivation, respectively ([@bib21]). Site-directed mutagenesis was performed using the QuikChange II kit (Agilent Technologies). The entire open reading frames of successful cDNA clones were confirmed by sequencing.

Electrophysiology {#s04}
-----------------

Mammalian HEK293FT cells (Invitrogen) were maintained in high-glucose Dulbecco's modified Eagle medium supplemented with 1% penicillin-streptomycin, 500 µg/ml geneticin, 6 mM GlutaMAX (Invitrogen), 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 10% (vol/vol) FBS; passage numbers between 3 and 30 were used. Cells were seeded into a 24-well plate and transfected with the respective NaChBac cDNA, as well as eGFP-N1 as a reporter plasmid, on the next day using Lipofectamine LTX (Invitrogen) according to the manufacturer's protocol. At day 1--2 after transfection, cells were released with trypsin and replated onto 12-mm round \#1.5 glass coverslips (Warner Instruments) a minimum of 1 h before recording isolated adherent cells with GFP fluorescence.

Pipettes were pulled from standard borosilicate glass (1.5 mm OD/0.86 mm ID; Sutter Instrument) to a resistance of 1.5--2.8 MΩ (when filled) using a P97 puller (Sutter Instrument) and fire polished. Whole-cell voltage-clamp was performed using an AxoPatch 200B amplifier (Molecular Devices) connected to a DigiData 1320A analogue-to-digital converter (Molecular Devices). Signals were sampled at 10 or 20 kHz and filtered at 2 or 5 kHz, respectively. Series resistance was corrected 75--80%. Capacitive current transients were cancelled by the internal amplifier circuitry, and leak currents were subtracted using a standard P/4 protocol.

Cells were continuously perfused with extracellular solution at room temperature (22--23°C) containing (mM) 140 NaCl, 10 Hepes, 3 KCl, 1.8 CaCl~2~, 1 MgCl~2~, and 10 tetraethylammonium chloride (TEA-Cl), adjusted to pH 7.35 with NaOH. Osmolality was 307 mOsm/kgH~2~O. Pipette solutions contained (mM) 120 CsF, 10 NaCl, 10 Hepes, 10 ethylene glycol tetraacetic acid, 10 TEA-Cl, 1 MgCl~2~, and 1 CaCl~2~, adjusted to pH 7.30 with CsOH and to 310 mOsm/kgH~2~O with sucrose. Saturated isoflurane (Abbott Laboratories) stock solutions were prepared in extracellular solution in gas-tight glass vials. Dilutions in gas-tight syringes were delivered using a pressurized perfusion system (ALA Scientific Instruments) with Teflon tubing, via a 200-µm-diameter manifold tip positioned ∼200--300 µm from the recorded cell. After control recordings, isoflurane was perfused for 2 min before subsequent recordings and continuously thereafter until washout. Solutions were delivered through a pressurized perfusion system to minimize mechanical disturbance of cells during isoflurane superfusion. Mock experiments with extracellular solution showed no effect on *I*~Na~. Working solutions of 0.8 mM isoflurane, a clinically effective concentration in mammals equivalent to about twice the minimum alveolar concentration ([@bib47]), were confirmed by gas chromatography ([@bib18]).

Data analysis {#s05}
-------------

Voltage-clamp data were collected and analyzed using pCLAMP v10.2 (Molecular Devices), with additional data processing and analysis using Prism v5.01 (GraphPad Software) and Excel 2010 and 2013 (Microsoft). Differences between groups were assessed using Student's *t* test except for fitted curves (i.e., conductance-voltage, concentration-response, and SSI), for which certain parameters were compared using an *F* test. In all cases, statistical significance was defined as P \< 0.05. Data are reported as mean ± SEM. Confidence of estimated model parameters are reported with 95% confidence intervals.

Currents were converted to conductance (*G*) using *G* = *I*/\[*V* − *V*~rev~\], where *I* is the measured current, *V* is the command potential, and *V*~rev~ is the reversal potential derived from linear extrapolations of individual current-voltage (*I-V*) curves. Voltage dependence of activation was quantified by first relating peak conductance (*G*) normalized by the maximum *G* (*G*~max~) to the pulse potential, which was followed by a quantitative description of this relation using a two-state Boltzmann equation of the form $G/G_{\max} = 1/\left\lbrack {1 + e^{{({V - V_{50}})}/k}} \right\rbrack,$ where *V* is voltage, *V*~50~ is the midpoint voltage, and *k* is the slope factor. SSI curves were fitted in a similar fashion. Concentration--response relations of peak current were fitted with a logistic equation of the form *Y* = 1/(1 + IC~50~/\[*ISO*\]*^slope^*), where *Y* is the response variable, \[*ISO*\] is the isoflurane concentration, IC~50~ is the isoflurane concentration at 50% inhibition, and *slope* is a factor related to the Hill coefficient. Response time courses were fitted with a time-shifted biexponential function: $\left\lbrack {A_{1}e^{{- {({t - t_{s}})}}/\tau_{1}} + A_{2}e^{{- {({t - t_{s}})}}/\tau_{2}} + B} \right\rbrack,$ where *A~n~* is the *n*th component amplitude, *B* is a constant representing a plateau, *t* is time, *t~S~* is the time shift, and *τ~n~* is the *n*th component time constant. Function values before *t~S~* were set to zero.

Kinetic modeling {#s06}
----------------

Na~v~ exhibits at least three conformational states: closed (C) before channel opening, open (O) conducting states triggered by depolarization, and inactivated (I) closed states visited after activation. The macroscopic Na^+^ current (*I*~Na~) time course can be viewed as: *I*~Na~(*t*) = \[γ(*V* − *V*~rev~)\]*nP~o~*(*t,V*), where *t* is time, *V* is membrane voltage, *V*~rev~ is the reversal potential, γ is single-channel conductance, *n* is channel number, and *P~o~* is the time course of the single-channel open probability. We collected *I*~Na~ families over a range of triggering voltages (−40 to 0 mV) for each channel in the absence and presence of isoflurane. Currents were then adjusted for driving force, resulting in responses reporting γ*nP~o~*(*t*) at each voltage and normalized to the peak of the 0-mV response in control (or in isoflurane if it was greater) to yield families reporting \[*P~o~*(*t*,*V*)/*Peak P~o~*(*t*, 0 mV)\]. This normalized *P~o~* can be analyzed to gain insight into the underlying gating and the effects of isoflurane.

[@bib26] proposed a six-state Markov model of NaChBac gating based and validated on the results of ionic and gating current analysis (see [Scheme 1](#sc1){ref-type="scheme"}):

![](JGP_201611600_Scheme1){#sc1}

In this model, the pore is presumed to be controlled by four activation gates, one contributed by each of the four component homomeric subunits, and all are required to be activated to reach the open conducting state (O). Each transition starting from C~1~ represents the opening of one of the activation gates until the final is opened upon transition from C~4~ to O. These transitions are governed by identical forward (α~1~) and backward (β~1~) rate constants such that each subunit's conformational transitions are identical and independent. Once open, O can then transition to the inactivated state (I) governed by forward (α~2~) and backward (β~2~) rate constants. The voltage dependence of forward and backward transition rates is given by $\alpha_{1}\left( V \right) = k_{\alpha_{1}}\left( 0 \right)e^{({{z_{1}x_{1}FV}/{RT}})}$ and $\beta_{1}\left( V \right) = k_{\beta_{1}}\left( 0 \right)e^{\lbrack{{- z_{1}{({1 - x_{1}})}FV}/{RT}}\rbrack}$ for activation and by $\alpha_{2}\left( V \right) = k_{\alpha_{2}}\left( 0 \right)e^{({z_{2}x_{2}FV/RT})}$ and $\beta_{2}\left( V \right) = k_{\beta_{2}}\left( 0 \right)e^{({- z_{2}{({1 - x_{2}})}FV/RT})}$ for inactivation, where *k*~α1~(0), *k*~β1~(0), *k*~α2~(0), and *k*~β2~(0) are transition rate constants at 0 mV; *z*~1~ and *z*~2~ are the valences of activation and inactivation transitions; *x*~1~ and *x*~2~ are fractions of the electric field where the energy barrier peak is located for activation and inactivation, respectively; *V* is membrane voltage; *F* is the Faraday constant; *R* is the universal gas constant; and *T* is absolute temperature. Solutions to the associated differential equations of the six-state Markov model were obtained using MATLAB v7.5 (MathWorks) by solving the matrix equation *X*(*t*) = *e^Q^*^(^*^t^*^)^*X*(0), where *X*(*t*) is a 6 × 1--state variable vector reporting the probability of C~1~ to C~4~, O, and I states at time *t*; *X*(0) is the initial state vector at time 0; and *Q*(*t*) is the 6 × 6--state transition matrix of rate constants governing the transition rates between all connected states. We used the Levenberg--Marquardt method (MATLAB Optimization Toolbox 4.1; MathWorks) to solve iteratively for a set of parameters, *k*~α1~(0), *k*~β1~(0), *k*~α2~(0), *k*~β2~(0), *z*~1~, *z*~2~, *x*~1~, and *x*~2~, and scaling factors, *K*~−40mV~ to *K*~0mV~, that provides a best fit to a family of mean normalized *P~o~* time courses obtained over a range of voltages (−40 to 0 mV). Scaling factors (*K*~−40mV~ to *K*~0mV~) were applied to model responses at the indicated voltage to account for the nature of normalized *P~o~* responses, the influence of model parameters on peak probability of state O, and experimental variability. During parameter estimation, *z* and *x* values were limited to ranges of 0 to 5*e*~0~ and 0 to 1, respectively. All other parameters were limited to positive values. This process resulted in a set of parameter values for each voltage family of mean normalized *P~o~* responses for each channel and condition. 95% confidence intervals of estimated parameters were calculated.

Estimation of free energy changes in gating transitions modulated by isoflurane {#s07}
-------------------------------------------------------------------------------

Eyring rate theory ([@bib14]) holds that a gating transition rate is determined by the energy barrier height that must be overcome to transition from one kinetic state to another and is described by Δ*G* = −*RT*ln\[*k~ij~*(0)/(κ*k~B~T*/*h*)\], where *k~ij~*(0) is the rate constant governing transitions from state *i* to *j* at zero membrane voltage, Δ*G* is the height of the free energy barrier for this transition, κ is the transmission coefficient (assumed to be 1), *k*~B~ is Boltzmann's constant, *h* is Planck's constant, and *R* and *T* are the same as above. Therefore, the change in Δ*G* induced by isoflurane (Δ*G*~ISO~) is obtained by determining the difference between Δ*G* in CTL and ISO, such that Δ*G~ISO~* = −*RT*ln\[*k~ij~*(0)*~ISO~*/*k~ij~*(0)*~CTL~*\], where *k~ij~*(0)*~ISO~* and *k~ij~*(0)*~CTL~* are obtained as described above.

Results {#s08}
=======

Effect of isoflurane on NaChBac voltage-dependent activation {#s09}
------------------------------------------------------------

Expression of WT NaChBac in HEK293FT cells produced robust whole-cell Na^+^ currents (*I*~Na~; [Fig. 1 A](#fig1){ref-type="fig"}, left) that were not observed in sham-transfected cells (not depicted). Control *I*~Na~ collected over a range of depolarizing potentials and the associated current-voltage (*I*-*V*) and normalized conductance-voltage (*G*-*V*) relationships ([Fig. 1](#fig1){ref-type="fig"}, left) agree with previous studies of NaChBac ([@bib44]; [@bib34]). Isoflurane (0.8 mM) effects, collected from the same cells as control, showed accelerated *I*~Na~ decay, with the rising phase of the *I*-*V* relationship shifted to the left without reduced peak *I*~Na~, indicating enhanced apparent inactivation and altered voltage-dependent activation, respectively. Fitting of *G-V* relationships revealed significant reduction in *V*~50~, further supporting altered activation ([Fig. 1 C](#fig1){ref-type="fig"}).

![**Isoflurane effects on voltage-dependent gating.** (A) Representative families of macroscopic *I*~Na~ in the absence (CTL) or presence of 0.8 mM isoflurane (ISO), elicited from HEK293FT cells expressing WT NaChBac or the mutant forms G229A and G219A as indicated. Inset shows triggering voltage-clamp protocol (stimulation frequency, 0.167 Hz; *V*~h~, holding potential). G229A tail currents clipped for clarity. Horizontal black lines indicate baseline; calibration bars as shown. (B) Normalized *I*-*V* relationships for each channel. Currents normalized by peak current in control for each cell (*n* = 5--6). (C) Normalized *G*-*V* relationships in CTL and 0.8 mM ISO. Conductance (*G*) normalized by maximum conductance (*G*~max~) and plotted versus voltage. Smooth lines are Boltzmann function fits to the averaged data with associated parameters (*V*~50~, voltage at half amplitude; slope factor: WT, *V*~50(CTL)~ = −28.0 ± 1.0 mV, *V*~50(ISO)~ = −33.8 ± 1.5 mV, slope~CTL~ = 8.4 ± 0.9 mV/e, slope~ISO~ = 9.6 ± 1.3 mV/e; G229A, *V*~50(CTL)~ = −18.4 ± 1.3 mV, *V*~50(ISO)~ = −21.0 ± 1.2 mV, slope~CTL~ = 12.0 ± 1.1 mV/e, slope~ISO~ = 12.8 ± 1.1 mV/e; G219A, *V*~50(CTL)~ = −31.1 ± 0.5 mV, *V*~50(ISO)~ = −34.5 ± 0.7 mV, slope~CTL~ = 9.5 ± 0.4 mV/e, slope~ISO~ = 11.1 ± 0.6 mV/e). Asterisks indicate differences between CTL and ISO fits with respect to *V*~50~ only (\*\*, P \< 0.01; \*\*\*\*, P \< 0.0001; *F* test). Isoflurane significantly altered the slope factor of G219A alone (P = 0.028; *F* test). All error bars represent SEM.](JGP_201611600_Fig1){#fig1}

Isoflurane acceleration of apparent *I*~Na~ inactivation (see [Fig. 4](#fig4){ref-type="fig"}, left) could be explained by promotion of the inactivated state ([@bib34]), or alternatively by slow block of open channels ([@bib7]). To begin to discriminate between these mechanisms, we studied NaChBac channels with G229A and G219A mutations that slow or accelerate inactivation, respectively ([@bib21]). In control conditions, current decay was slowed in G229A and accelerated in G219A relative to WT ([Fig. 1 A](#fig1){ref-type="fig"}, middle and right), consistent with a previous study ([@bib21]). Isoflurane (0.8 mM) accelerated current decay in both G229A and G219A similar to WT ([Fig. 1 A](#fig1){ref-type="fig"}). The current peak of *I-V* relationships was slightly increased by isoflurane in G229A but markedly reduced (by ∼50%) in G219A ([Fig. 1 B](#fig1){ref-type="fig"}). Fitting of the G219A *G-V* relationship showed a hyperpolarizing shift of *V*~50~ similar to that of WT, which was not observed for G229A.

Isoflurane qualitatively accelerated apparent inactivation irrespective of the control inactivation rate, which argues against a simple open channel blocking mechanism. Furthermore, isoflurane induced a leftward shift of the *G-V* relationship, indicating a relative stabilization of the open state in WT and G219A. These findings point to direct effects of isoflurane on both activation and inactivation.

Concentration dependence of isoflurane effects on peak current {#s10}
--------------------------------------------------------------

The concentration dependence of isoflurane effects was investigated by delivering single depolarizing pulses to −10 mV after exposure to increasing concentrations of isoflurane, with a maximum of three concentrations tested per cell ([Fig. 2](#fig2){ref-type="fig"}). Pulses were also delivered after isoflurane washout to ensure that peak currents had returned to control levels at the end of the experiment. In contrast to the results obtained in *I-V* plots ([Fig. 1](#fig1){ref-type="fig"}), a slight peak current reduction was observed for WT NaChBac at 0.8 mM isoflurane. In all three channels, most strikingly in G219A, isoflurane depressed peak *I*~Na~ in a concentration-dependent manner. G229A current amplitudes were slightly increased at 0.8 mM, similar to results shown in [Fig. 1](#fig1){ref-type="fig"}, but were reduced at higher concentrations. *IC*~50~ values obtained from logistic curve fits suggest differential sensitivities (G219A \> WT \> G229A), consistent with the results in [Fig. 1](#fig1){ref-type="fig"}. The differences in *IC*~50~ were statistically significant across all three groups. Isoflurane also enhanced *I*~Na~ decay rate in a concentration-dependent manner in all three channels.

![**Concentration dependence of isoflurane peak *I*~Na~ inhibition.** (A) Representative normalized *I*~Na~ time courses over a range of isoflurane (ISO) concentrations (indicated) for WT, G229A, and G219A. Individual *I*~Na~ responses obtained from a single cell exposed to ISO with initial control (CTL) and bracketing washout (WASH) are shown; other concentrations were obtained from individual cells. Responses are normalized to peak *I*~Na~ in CTL. Horizontal black lines indicate baseline. Inset shows voltage protocol (frequency, 0.167 Hz; *V*~h~, holding potential). (B) Concentration-response relationships for peak *I*~Na~ inhibition for each channel. Peak *I*~Na~ in isoflurane (Peak *I*~ISO~) was normalized by that of control (Peak *I*~CTL~) and plotted versus isoflurane concentration (*n* = 3--10; mean ± SEM). Curves are logistic function fits with indicated IC~50~ values, which were significantly different across all three channels (P \< 0.0001; *F* test).](JGP_201611600_Fig2){#fig2}

Isoflurane effects on inactivation {#s11}
----------------------------------

Inactivation recovery time courses were well fitted by a biexponential function for all channels ([Fig. 3 A](#fig3){ref-type="fig"}), consistent with both slow and fast inactivated states. The slow time constant (τ~S~) agrees with the monoexponential recovery reported for longer conditioning depolarizations ([@bib44]). Isoflurane accelerated WT channel recovery from inactivation by increasing the fast component amplitude (A~F~) at the expense of the slow (A~S~) without changes in time constants ([Fig. 3 A](#fig3){ref-type="fig"}, left, inset). Isoflurane failed to alter G219A inactivation recovery, as indicated by superimposable control and isoflurane responses ([Fig. 3 A](#fig3){ref-type="fig"}, right). For G229A, test pulse durations failed to inactivate all channels in control. Isoflurane enhanced inactivation, leading to a greater fraction of inactivated channels. However, a scaled version of the isoflurane response reproduced the control response ([Fig. 3 A](#fig3){ref-type="fig"}, middle), indicating that isoflurane failed to change recovery time constants and relative amplitudes of the two exponential components.

![**Isoflurane effects on current inactivation.** (A) A two-pulse voltage protocol was used to characterize the recovery time course from inactivation. Cells were held at the indicated holding potential (*V*~h~), and two 500-ms test pulses to −10 mV were delivered separated by a range of recovery intervals at *V*~h~ (protocol delivery frequency, \<0.1 Hz). Available fractional current (peak current amplitude of pulse 2/peak amplitude of pulse 1) was plotted against recovery interval for control (CTL) and isoflurane (ISO; *n* = 3--7; mean ± SEM). Curves are biexponential fits of recovery responses: WT (CTL, A~F~ = −0.57 ± 0.063, τ~F~ = 47 ± 6.3 ms, A~S~ = −0.41 ± 0.063, τ~S~ = 320 ± 60 ms, B = 0.98 ± 0.006; ISO, A~F~ = −0.8 ± 0.08, τ~F~ = 54 ± 7 ms, A~S~ = −0.21 ± 0.08, τ~S~ = 400 ± 200 ms, B = 1.0 ± 0.01); G229A (CTL, A~F~ = −0.29 ± 0.034, τ~F~ = 300 ± 56 ms, A~S~ = −0.14 ± 0.027, τ~S~ = 3,700 ± 2,400 ms, B = 0.98 ± 0.02; ISO, A~F~ = −0.53 ± 0.044, τ~F~ = 220 ± 29 ms, A~S~ = −0.25 ± 0.042, τ~S~ = 2,300 ± 720 ms, B = 0.99 ± 0.015); G219A (CTL and ISO, A~F~ = −0.4 ± 0.082, τ~F~ = 110 ± 28 ms, A~S~ = −0.58 ± 0.083, τ~S~ = 680 ± 105 ms, B = 0.98 ± 0.01). G229A ISO response is also shown scaled to the same amplitude as CTL. Inset is a bar graph showing the amplitude and time constants from the WT biexponential fit for control (white bars) and 0.8 mM isoflurane (red bars) with differences by paired Student's *t* test: \*, P \< 0.05 (*n* = 7). Error bars are SEM. (B) A three-pulse voltage protocol characterized the onset time course of current inactivation. Cells were held at the indicated *V*~h~ followed by pulse 1 (−10 mV, 500 ms), a variable duration prepulse (*V*~pre~), pulse 2 (−10 mV, 500 ms), and after at least 10 s at *V*~h~, pulse 3 (−10 mV, 500 ms) to confirm preparation stability. Protocol deliveries were separated by \>10 s. Available fractional current was plotted against prepulse duration for CTL and ISO (*n* = 3--6; mean ± SEM). Smooth curves are monoexponential fits (time constant, τ) of onset responses (WT, τ~ISO~ = 16 ± 30 s; G229A, τ~ISO~ = 60 ± 46 s; G219A, τ~ISO~ = 12 ± 46 s). (C) SSI relationships were characterized using a variation of the three-pulse voltage protocol used in B, in which the prepulse duration was 90 s throughout; protocol deliveries were separated by \>10 s. Normalized SSI curves were obtained by plotting available fractional current against prepulse potential for CTL and 0.8 mM ISO (*n* = 3--11; mean ± SEM). Curves are Boltzmann function fits to the averaged data with associated parameters (*V*~50~, voltage at half amplitude; slope factor: WT, *V*~50(CTL)~ = −72.6 ± 1.3 mV, *V*~50(ISO)~ = −89.3 ± 1.3 mV, slope~CTL~ = −6.4 ± 0.8 mV/e, slope~ISO~ = −6.0 ± 1.1 mV/e; G219A, *V*~50(CTL)~ = −96.6 ± 1.4 mV, *V*~50(ISO)~ = −122.1 ± 0.8 mV, slope~CTL~ = −6.5 ± 0.8 mV/e, slope~ISO~ = −4.6 ± 1.0 mV/e). *V*~50~ values were significantly different between CTL and ISO fits for both WT and G219A (P \< 0.0001; *F* test), whereas slope factors were not different.](JGP_201611600_Fig3){#fig3}

We next examined the onset kinetics of current inactivation ([Fig. 3 B](#fig3){ref-type="fig"}). Because conditioning pulses lasting minutes are required to reach steady state ([@bib36]), we determined the minimum conditioning pulse duration needed for SSI protocols. These protocols did not address onset kinetics at a range of conditioning voltages and thus were not intended to be an exhaustive examination of isoflurane effects on onset kinetics.

Onset time courses were characterized at control holding potentials and at potentials of 40 mV more positive. The latter was chosen based on preliminary data indicating a threshold of SSI curves near these voltages. For all three channels, little inactivation was observed for control conditions, whereas isoflurane decreased channel availability monoexponentially with *V*~pre~ duration. WT and G219A time constants were \<20 s, in contrast to 60 s for G229A, with steady-state conditions reached in ∼60 s and ∼200 s, respectively, assuming three time constants to steady state. SSI protocols involving 200-s pulses were prohibitively long, and therefore data for G229A SSI were not obtained.

Data for WT and G219A SSI were collected using a three-pulse protocol with a 90-s conditioning pulse ([Fig. 3 C](#fig3){ref-type="fig"}). Preparation stability provided data for up to three voltages per cell, and results from multiple cells were then combined to create SSI curves. Isoflurane shifted SSI curves in the hyperpolarized direction, reducing *V*~50~ by ∼16 mV and ∼25 mV for WT and G219A, respectively, with little change in Boltzmann slope factors. The results indicate that isoflurane induces a relative stabilization of the inactivated states.

Kinetic analysis of current time course {#s12}
---------------------------------------

Isoflurane qualitatively accelerated activation and inactivation in WT NaChBac, consistent with previous findings ([@bib34]), as well as in both mutant channels ([Fig. 4 A](#fig4){ref-type="fig"}). We analyzed isoflurane-induced changes in activation and inactivation kinetics using a biexponential function with rising and falling components to provide initial quantitative insight into channel gating (see Materials and methods). Biexponential function fits reproduced the time course of all channels in control and isoflurane, with the exception of the initial activation phase occurring in the first few milliseconds ([Fig. 4 B](#fig4){ref-type="fig"}, arrow), likely arising from channel transitions through multiple closed states before opening ([@bib26]). Compared with WT, G229A and G219A mutations slowed or accelerated inactivation (τ~inact~), respectively, but neither mutation significantly altered activation kinetics (τ~act~; [Fig. 4 C](#fig4){ref-type="fig"}). Isoflurane effects on associated time constants indicate acceleration of activation and inactivation for all three channels.

![**Kinetic analysis of current time courses.** (A, top) Representative currents triggered by depolarization (to −10 mV using same protocol as in [Fig. 1 A](#fig1){ref-type="fig"}) for control (CTL) and 0.8 mM isoflurane (ISO) for the indicated channels. Current responses are plotted as the additive inverse. Current time courses are well described by fits of the biexponential function (dashed blue lines). In the following equations, the slower exponential is falling and describes inactivation (τ~inact~), and the faster exponential is rising and describes activation (τ~act~). Fitted parameters (time constant in ms): WT, *I*~CTL~= 2,800 pA•\[exp(−(*t* − 0.87)/126) − exp(−(*t* − 0.87)/4)\], *I*~ISO~ = 3,300 pA•\[exp(−(*t* − 0.39)/27) − exp(−(*t* − 0.39)/2.8)\]; G229A, *I*~CTL~= 1,570 pA•\[exp(−(*t* − 0.86)/510) − exp(−(*t* − 0.86)/6.4)\], *I*~ISO~ = 1,690 pA•\[exp(−(*t* − 0.55)/183) − exp(−(*t* − 0.55)/4.6)\]; G219A, *I*~CTL~= 2,400 pA•\[exp(−(*t* − 0.57)/20) − exp(−(*t* − 0.57)/3.4)\], *I*~ISO~ = 1,750 pA•\[exp(−(*t* − 0.27)/7) − exp(−(*t* − 0.27)/1.9); see Materials and methods. (bottom) Plots of fit residuals. (B) Responses from A replotted on an expanded timescale to focus on the early activation phase. The preponderance of the early time course is well described by the biexponential functions (dashed blue lines), except for the initial activation phase (marked by the arrow), which was not considered during biexponential function fitting; see Materials and methods. Insets show same data as in main figure plotted on an expanded timescale to show initial phase of activation time course. (C) Group time constants for inactivation (τ~inact~) and activation (τ~act~) phases for CTL and ISO, as indicated (*n* = 3--5; paired *t* test: \*, P \< 0.05; \*\*\*, P \< 0.001). Control inactivation and activation time constants for G229A and G219A were also compared with WT (unpaired Student's *t* test: ns, not significant; ††, P \< 0.01; †††, P \< 0.001). Error bars are SEM.](JGP_201611600_Fig4){#fig4}

Gating analysis using the six-state Markov model {#s13}
------------------------------------------------

Macroscopic rates are a function of both microscopic rate constants and relevant channel state probabilities. To gain insight into microscopic gating, we applied a previously described six-state Markov model of NaChBac gating ([@bib26]) to our experimental results ([Fig. 5 A](#fig5){ref-type="fig"}). Because *I*~Na~ is proportional to probability of model state O (model *P~o~*), we transformed current time courses into normalized open channel probability (normalized *P~o~*; see Materials and methods). We then calculated mean normalized *P~o~* responses ([Fig. 5 B](#fig5){ref-type="fig"}). Fitting model *P~o~* responses to a family of mean normalized *P~o~* responses obtained over a range of voltages (−40 to 0 mV) involved estimation of a single set of optimal values for *k*~α1~(0), *k*~β1~(0), *k*~α2~(0), *k*~β2~(0), *z*~1~, *z*~2~, *x*~1~, and *x*~2~ and scaling factors *K*~−40mV~ to *K*~0mV~ (see Materials and methods). After parameter estimation, model *P~o~* responses reproduced families of mean normalized *P~o~* for all channels in the absence or presence of isoflurane, including the initial activation phase ([Fig. 5 B](#fig5){ref-type="fig"}), such that this model is sufficient to account for the macroscopic gating for all channels for control or isoflurane conditions. Therefore, it is reasonable to conclude that analysis of macroscopic gating using the six-state model provides insight into isoflurane effects on microscopic gating. Rate constants derived from this analysis are proportional only to the absolute microscopic rate constants because open probabilities have not been determined. Isoflurane effects on model rate constants for a particular channel are meaningful because comparisons are made between responses from the same cell in the absence or presence of isoflurane, but comparisons between channels are not.

![**Fitting of NaChBac current responses using the six-state Markov model.** (A) A sequential six-state Markov model proposed by [@bib26] to account for NaChBac gating based on ionic and gating current results. Four closed states (C~n~) are visited as governed by forward (α~1~) and backward (β~1~) rate constants before the open state (O). O transitions to the inactivated state (I) governed by forward (α~2~) and backward (β~2~) rate constants. (B) The six-state model was used to analyze isoflurane microscopic gating effects manifest in families of mean (±SEM; *n* = 4--6) normalized *P*~o~ responses (empirical, coarse black and red lines) over a range of triggering voltages (−40 to 0 mV, voltage protocol shown in top, left, bottom inset) in control (top) and 0.8 mM isoflurane (bottom) for each channel as indicated. The fitted six-state model *P*~o~ responses (simulated, smooth gray and black lines) reproduced mean normalized *P*~o~ responses, including the activation phase (top insets*)*, where "goodness of fit" is supported by residual plots (bottom*,* time bars 200 ms, 200 ms, and 100 ms for WT, G229A, and G219A, respectively). Optimal model parameter sets were estimated using the entire voltage family of mean normalized *P*~o~ responses as targets (see Materials and methods). Top insets show responses replotted on an expanded timescale to focus on the early activation time course. Below are serial presentations of associated fit residual plots at the indicated voltages.](JGP_201611600_Fig5){#fig5}

Estimated WT gating parameters ([Fig. 6](#fig6){ref-type="fig"}, top) for control WT NaChBac were generally similar to those of [@bib26]. *k*~α1~(0) and *k*~α2~(0) were exceptions because they are approximately threefold less, but only approximately twofold less than values reported by [@bib7]. Overall, our results are comparable to those of [@bib26], pointing to similar channel function in these preparations. The 95% confidence intervals of estimated parameters can be viewed as falling into three ranges based on the calculated fraction of the estimated parameter value: \<0.15, 0.15--0.5, and \>0.5, which also apply to G229A and G219A ([Fig. 6](#fig6){ref-type="fig"}, middle and bottom). The first range contains dominant model parameters that are estimated with high confidence (narrow confidence interval) and include α~1~, α~2~, *z*~1~, and *x*~1~. The second parameter confidence is less, which could be explained by smaller values of member backward rate constants (β~1~ and β~2~) over this voltage range. The final range comprises parameters estimated with low confidence and includes *z*~2~ and *x*~2,~ which have large confidence intervals that include zero, suggesting that inactivation is voltage independent over this range of potentials.

![**Isoflurane effects on NaChBac gating parameters analyzed using the six-state Markov model*.*** Plots of estimated gating parameters with 95% confidence intervals for *k*~x~(0) of rate constants (left) and *z*~x~ and *x*~x~ (right). Parameter estimation involved fitting model *P*~o~ responses to one family of mean normalized *P*~o~ responses for each experimental condition (see [Fig. 5](#fig5){ref-type="fig"}). 95% confidence intervals were determined for the final value of each estimated parameter. Negative confidence intervals were limited to zero. β~2~ values were scaled up by 100 for clarity because values were uniformly less than one. Insets show estimated change in free energy of associated gating transition (Δ*G*~ISO~) induced by isoflurane (see Materials and methods). Estimated values with 95% confidence interval of model parameters *k~α~*~~1~~(0), *k~~β~~*~~1~~(0), *k~α~*~~2~~(0), *k~~β~~*~~2~~(0) (s^−1^) and *z*~~1~~, *x*~~1~~, *z*~~2~~, *x*~~2~~ (z~x~\[e0\] and x~x~ \[unitless\]) are as follows: WT CTL: 978 ± 9.2, 45.1 ± 11.1, 9.33 ± 0.14, 0.19 ± 0.068, 1.94 ± 0.16, 0.32 ± 0.028, 0.26 ± 0.65, 0.74 ± 1.87; ISO: 1,450 ± 9.9, 36.1 ± 8.5, 33.1 ± 0.28, 0.11 ± 0.064, 1.86 ± 0.12, 0.29 ± 0.02, 0.067 ± 0.83, 0.45 ± 5.67; G229A CTL: 555 ± 5.13, 56.9 ± 8.9, 1.69 ± 0.048, 1.01 × 10^−6^ ± 0.084, 1.53 ± 0.10, 0.31 ± 0.025, 4.7 × 10^−4^ ± 2,700, 5.8 × 10^−5^ ± 354; ISO: 707 ± 5.25, 40.7 ± 7.7, 5.42 ± 0.075, 36.8 ± 3.8, 1.41 ± 0.094, 0.21 ± 0.017, 0.3 ± 0.15, 0.046 ± 0.088; G219A CTL: 1,190 ± 7.72, 38.5 ± 6.84, 40.3 ± 0.33, 8.77 ± 4.62, 1.84 ± 0.093, 0.37 ± 0.021, 0.22 ± 0.75, 0.44 ± 1.53; ISO: 1,740 ± 19.1, 80.4 ± 26.1, 133 ± 2.87, 0.039 ± 9.81, 1.4 ± 0.17, 0.39 ± 0.049, 4.2 × 10^−6^ ± 302, 6.7 × 10^−5^ ± 1,110, respectively. Estimated values with 95% confidence intervals of model scale factors *K*~−40mV~, *K*~−30mV~, *K*~−20mV~, *K*~−10mV~, and *K*~0mV~ are as follows: WT CTL: 0.91 ± 0.1, 0.86 ± 0.05, 0.94 ± 0.05, 1.12 ± 0.03, 1.18 ± 0.02; ISO: 0.82 ± 0.04, 0.98 ± 0.02, 1.09 ± 0.02, 1.17 ± 0.02, 1.18 ± 0.02; G229A CTL: 1.13 ± 0.14, 1.03 ± 0.06, 0.98 ± 0.04, 0.99 ± 0.02, 1.07 ± 0.02; ISO: 0.82 ± 0.04, 0.85 ± 0.02, 0.94 ± 0.02, 1.05 ± 0.02, 1.09 ± 0.02; G219A CTL: 0.91 ± 0.04, 1.03 ± 0.05, 1.07 ± 0.02, 1.13 ± 0.02, 1.17 ± 0.02; ISO: 0.87 ± 0.06, 0.85 ± 0.06, 0.88 ± 0.05, 0.937 ± 0.04, 0.93 ± 0.02, respectively.](JGP_201611600_Fig6){#fig6}

Isoflurane increased WT forward rate constants of activation (α~1~) and inactivation (α~2~) by ∼50% and ∼300%, respectively, without changes in voltage dependence, and slightly reduced backward rate constants (β~1~ and β~2~). G229A and G219A showed similar results, except in the backward rate constant for inactivation, β~2~. In G229A, β~2~ was nonzero only in the presence of isoflurane.

Effects on α~1~ and α~2~, in the absence of changes in voltage dependence, indicate reduced conformational chemical potential energy between associated kinetic states. To estimate the magnitude of this effect, we calculated changes in the free energy barriers induced by isoflurane (Δ*G*~ISO~; [Fig. 6](#fig6){ref-type="fig"}, left, insets). Δ*G*~ISO~ for rate constants was similar across channel types. Δ*G*~ISO~ for α~2~ was approximately −0.7 kcal/mol, which is nearly fourfold greater than for α~1~ (approximately −0.2 kcal/mol). These results indicate that isoflurane primarily reduces the chemical potential energy barrier of inactivation (α~2~) and, to a lesser degree, activation (α~1~).

Discussion {#s14}
==========

We combined electrophysiological and kinetic modeling studies to reveal several novel mechanistic insights into isoflurane modulation of NaChBac function. Isoflurane accelerated both activation and inactivation kinetics and shifted activation and SSI relationships to more hyperpolarized potentials without slowing recovery from inactivation. To provide insight into structure--function relationships and the possibility of slow open channel block, we studied two channel mutations, G229A and G219A, which inhibit or enhance inactivation, respectively. A six-state NaChBac gating model ([@bib26]) was used to analyze macroscopic gating to estimate underlying microscopic gating. This model was sufficient to quantitatively account for gating in the absence or presence of isoflurane, thus arguing against the importance of slow open channel block. The results indicate that isoflurane modulation of NaChBac involves enhancement of microscopic activation and inactivation without stabilization of the inactivated state at resting membrane potentials.

Enhancement of NaChBac activation by isoflurane {#s15}
-----------------------------------------------

Isoflurane increased the microscopic activation rate constant (α~1~) and induced a hyperpolarized shift of the *G*-*V* relationship in WT NaChBac, in agreement with results for sevoflurane, a related ether anesthetic, on NaChBac ([@bib7]). Similar hyperpolarized shifts in *G-V* relationships have been reported for sevoflurane on Shaker-type voltage-gated potassium channels ([@bib6]; [@bib28]) but were not found in a previous study of isoflurane effects on NaChBac ([@bib34]), probably because of the use of a different voltage protocol (see last paragraph, this section). These effects were also observed in G219A, but with smaller hyperpolarizing *G*-*V* shifts compared with WT. G229A manifested increased α~1~ but lacked a significant shift in the *G-V* relationship.

Isoflurane reduced the chemical potential energy barrier of activation of all channels to similar degree (*k*~α1~(0), Δ*G*~ISO~ ≈ −0.2 kcal/mol), indicating that the G219A and G229A mutations do not alter the mechanism underlying the isoflurane effect. The voltage dependence of activation was little changed by isoflurane, with the possible exception of G219A. Isoflurane also raised α~1~, with absolute increases more than 10-fold greater than for α~2~. Small but significant leftward shifts in *G*-*V* relationships might simply be caused by greater peak open probability at a particular voltage arising from a disproportionately larger absolute increase in channel opening rates relative to inactivation. In this case, increases in the absolute channel opening rate that are unmatched by those of closing rates (inactivation) can lead to increased peak open channel probability. A related possibility is that changes in macroscopic activation induced by isoflurane arise strictly from alterations of inactivation. We explored this possibility by fixing activation rate constants (α~1~ and β~1~) and reestimating the resultant parameter subset in the presence of isoflurane. Model responses (unpublished data) did not account for the activation phase upon visual inspection, and *F*-test analysis indicated that the fit was statistically better when activation rate constants were estimated (P \< 0.05), thereby supporting changes in activation.

[@bib34] reported that isoflurane reduced WT NaChBac peak currents, in contrast to the results of this study. This divergent result can be explained by differences in the holding potential used. We used holding potentials of −140 and −160 mV to minimize the fraction of inactivated channels. In contrast, [@bib34] analyzed the effects of isoflurane at more depolarized membrane potentials (−80 mV). Our WT SSI curve indicates that at a holding potential of −80 mV the predicted fraction of inactivated channels is ∼0.2, and this fraction is promoted by isoflurane. Under these conditions, isoflurane depressed peak current, but based on our current findings this result likely arose from the presence of a significant fraction of inactivated channels induced by the depolarized holding potentials and isoflurane.

Isoflurane effects on NaChBac inactivation {#s16}
------------------------------------------

Isoflurane increased the inactivation rate constant (α~2~) for all channels and induced a hyperpolarized shift of SSI in WT and G219A, with the effect on G229A unknown. Isoflurane also accelerated recovery from inactivation in WT channels at resting membrane potentials, similar to sevoflurane effects ([@bib7]). This effect was not evident in the six-state kinetic model, which showed no statistical effect of isoflurane on the parameter β~2~ at depolarized potentials. Isoflurane reduced the chemical potential energy barrier for inactivation of all channels to a similar degree (*k*~α2~(0), Δ*G*~ISO~ ≈ −0.7 kcal/mol), indicating that the mutations do not alter the mechanism of this isoflurane effect. This effect is fourfold greater than for α~1~, making this the predominant effect of isoflurane on channel gating. For all channels, α~2~ exhibited little voltage dependence in control as reported by *z*~2~ and *x*~2~ values, consistent with voltage modulation of macroscopic inactivation being determined solely by changes in open channel probability ([@bib2]).

Recovery from inactivation in WT channels after 500-ms depolarizations was biexponential, with fast (τ~F~ ≈ 50 ms) and slow (τ~S~ ≈ 350 ms) components. The kinetics of the slow component are consistent with a previous study involving longer depolarizations ([@bib44]). Our results indicate two forms of inactivation, slow and fast, with the fast component dominant in our experimental protocols, and likely accounting for the observed monoexponential macroscopic inactivation time course. Isoflurane accelerated overall recovery from inactivation by increasing the fraction of the fast component at the expense of the slow without altering individual recovery time constants, suggesting that isoflurane selectively promotes the fast inactivated state. These findings are not easily explained by a simple open block mechanism.

Proposed allosteric model of isoflurane modulation of NaChBac {#s17}
-------------------------------------------------------------

We probed the pharmacologic mechanisms underlying isoflurane modulation of NaChBac using a six-state Markov NaChBac model based on gating current and charge movement results and validated by reconciling macroscopic currents ([@bib26]). Optimal estimated rate constants allowed the six-state model to reproduce channel gating over a range of potentials for all channels, in the absence or presence of isoflurane ([Scheme 2](#sc2){ref-type="scheme"}):

![](JGP_201611600_Scheme2){#sc2}

[Scheme 2](#sc2){ref-type="scheme"} represents our proposed allosteric mechanism of isoflurane modulation of WT NaChBac. This model is an extension of the model proposed by [@bib26] ([Scheme 1](#sc1){ref-type="scheme"}). The additional features of [Scheme 2](#sc2){ref-type="scheme"} are based on direct empirical observations as well as those arising from the analysis of empirical results using [Scheme 1](#sc1){ref-type="scheme"}. The structure of the activation/inactivation backbone is unchanged; the bolded α~1~ and α~2~ transition arrows signify isoflurane enhancement in accord with our findings. The preexisting inactivated state *I* has been relabeled the fast inactivated state *I~F~*, and a second slow inactivated state (*I~S~*) has been introduced with associated inactivation and recovery rate constants α~3~ and β~3~, respectively. These revisions reconcile biexponential recovery from inactivation at resting membrane potentials in which isoflurane promotes *I~F~* at the expense of *I~S~* without changing recovery time constants. Analysis of the biexponential recovery from inactivation provides quantitative insight into β~2~ and β~3~ at polarized membrane potentials (−140 mV). The WT SSI curve ([Fig. 3 C](#fig3){ref-type="fig"}) indicates that a membrane potential of −140 mV returns all channels to a resting available state over time. Therefore, forward inactivation rates (α~2~ and α~3~) can be considered negligible relative to the corresponding backward rates (β~2~ and β~3~). In light of this reasoning, the coefficients of the biexponential function then reflect the relative probabilities of *I*~S~ and *I*~F~ at the end of the conditioning pulse, and time constants report reciprocal values of recovery rate constants (β~2~ and β~3~). Therefore, recovery inactivation rate constants were calculated for WT control (β~2~ = 21.3 s^−1^, β~3~ = 3.13 s^−1^), which are changed little by isoflurane. The unbolded α~3~, β~1~, β~2~, and β~3~ transition arrows indicate no isoflurane modulation. At depolarized potentials (−40 to 0 mV), estimated values of β~2~ are more than 20-fold smaller than α~2~, supporting the proposal that *I~F~* is nearly absorbing in this voltage range.

Open channel block of NaChBac by isoflurane {#s18}
-------------------------------------------

[@bib7] proposed a mechanism for sevoflurane modulation of WT NaChBac that involves open channel block based on results from molecular dynamics simulations. The simulations showed sevoflurane in the channel pore interacting with conserved NaChBac residues (T220 and F227), in which homologous residues in mammalian Na~v~ play critical roles in local anesthetic (LA) pore block of open channels. Further support came from extension of the six-state NaChBac gating model ([@bib26]) to include a slow open channel block mechanism. The slow open channel block model semi-quantitatively accounted for some of isoflurane effects, including acceleration of macroscopic inactivation, hyperpolarizing shifts of *G-V* and SSI relationships, and accelerated recovery from apparent inactivation at resting membrane potentials.

Although a pore-blocking mechanism by neutral isoflurane is possible, it is unlikely that isoflurane pharmacology parallels that of charged LA open channel block. Most LAs exhibit uncharged and charged states (tertiary and quaternary amines) at physiological pH in which the charged form participates in high-affinity open channel pore binding, and such block is mediated by F1579 (Na~v~1.4; [@bib23]), homologous to F227 in NaChBac. Recent ^19^F NMR binding data show very weak interactions between isoflurane and F227 in NaChBac ([@bib24]). Furthermore, high-affinity intrapore LA binding is mediated by cation-π binding involving the charged LA head and F1579 aromatic ring ([@bib1]).

To further explore the ability of a simple open channel block to account for isoflurane effects on NaChBac, we extended our [Scheme 1](#sc1){ref-type="scheme"} to include an open channel blocked state (B) as proposed by [@bib7] (their Fig. 4 B). Those authors reported sevoflurane-induced increases in β~2~, in contrast to our finding that β~2~ was little changed. We next estimated all parameters to include those associated with open channel block (*K*~on~ and *K*~off~). Given our empirical target dataset for WT NaChBac, inclusion of an open block mechanism led to reduced peak open probability (with *K*~on~ limited to nonzero positive values), a slight change in β~2~, and a value of *K*~off~ that approached zero. The effects of increased β~2~ and a nonzero *K*~off~ both promote open state probability because they mediate channel reopening from nonconducting states I and B, which leads to incomplete inactivation and a visible *I*~Na~ plateau. An *I*~Na~ plateau was observed in simulations by [@bib7] (their Fig. 4 C), but this observation is absent in representative current time courses (their Fig. 3, A and C) as well as in our empirical results ([Fig. 5 B](#fig5){ref-type="fig"}, left). A recent NMR binding study identified a strong isoflurane binding site at the base of the selectivity filter at residue T189, which lies at the extracellular mouth of the pore ([@bib24]), leading those authors to postulate that isoflurane binds at this site to occlude ion conduction. However, our data and kinetic modeling results do not favor an open channel blocking mechanism for isoflurane modulation of NaChBac.

Structural basis for allosteric modulation of NaChBac by isoflurane {#s19}
-------------------------------------------------------------------

NaChBac appears to manifest only slow or C-type--like inactivation ([@bib9]; [@bib36]) that is similar to that of eukaryotic Na~v~ ([@bib32]; [@bib49]). Slow inactivation is thought to involve the P-loops in eukaryotic channels ([@bib32]; [@bib49]) as well as in prokaryotic channels such as NaChBac ([@bib36]). Specifically, a collapse of the selectivity filter is thought to underlie prokaryotic Na^+^ channel inactivation (for review, see [@bib4]). Sevoflurane and isoflurane were predicted through molecular dynamics simulations to bind to residues in the NaChBac P-loops ([@bib41]; [@bib7]). Two of these interactions were recently confirmed by ^19^F NMR studies ([@bib24]), in which isoflurane had strong interactions with T189 at the base of the selectivity filter and S208, an extracellular residue connecting the P2 loop to the S6 helix. The isoflurane binding site at the base of the selectivity filter might represent a distinct binding site governing effects on NaChBac inactivation, similar to that proposed for LA modulation of slow inactivation in Na~v~1.4 ([@bib12]).

Charged residues in S4 contribute to the NaChBac voltage sensor ([@bib11]; [@bib8]), and in S5--S6 contribute to the permeation pore ([@bib50]). S4 voltage sensor movements trigger pore opening involving the S4--S5 linker, which has been predicted as a site of action for volatile general anesthetics for both NaChBac ([@bib41]; [@bib7]) and voltage-gated potassium channels ([@bib5]; [@bib28]). The S4--S5 linker was also identified as an isoflurane binding site by ^19^F NMR, with isoflurane interacting strongly with S129 ([@bib24]). This leads us to speculate that the S4--S5 linker represents a second isoflurane binding site that selectively governs anesthetic effects on activation. Alternatively, the extracellular binding site at S208 could also be involved, as it connects the pore loops with S6 and could thus influence the rigid-body motions of the activation gate ([@bib24]). Site-directed mutagenesis of these two putative sites with electrophysiological characterization of activation kinetics might answer this question.

Limitations {#s20}
-----------

The validity of our kinetic modeling relied on the fitting of current families from the same cell before and after exposure to isoflurane. Because of the slow kinetic properties of NaChBac, it was not feasible to collect data using multiple electrophysiological protocols during the course of one experiment without compromising preparation stability. Therefore, although it would have been ideal to simultaneously model current families from deactivation, SSI, or recovery protocols, we focused on the analysis of currents resulting from depolarizing steps. This necessarily highlights changes to forward rate constants, which are accelerating under these conditions, and may not reveal more subtle effects on backward rate constants. The faster kinetics of mammalian Na~v~ would permit more detailed analysis in this regard.

Mammalian Na~v~ isoforms manifest both fast and slow forms of inactivation, and isoflurane enhances Na~v~1.2 fast inactivation ([@bib40]). Even so, bacterial Na^+^ channels have structural similarities to mammalian Na~v~ that support their use as experimental models ([@bib3]; [@bib10]; [@bib37]). Recent computational studies using bacterial Na^+^ channel crystal structures reveal similarities in the outer pore ([@bib48]; [@bib25]; [@bib29]; [@bib30]) and pore fenestrations ([@bib22]). Moreover, the presence of slow inactivation in mammalian Na~v~ highlights the utility of our results. Drug modulation of Na~v~ slow inactivation is important in treating neuropathic pain, arrhythmias, and epilepsy ([@bib43]; [@bib27]; [@bib13]) and is involved in neuronal plasticity ([@bib49]). Further studies are required to examine anesthetic effects on slow inactivation in mammalian Na~v~ and expand investigation to other channel states, examine single-channel effects, and determine whether isoflurane and sevoflurane have conserved mechanisms of action.

Conclusions {#s21}
-----------

We find that isoflurane reduces Na^+^ currents through NaChBac by increasing both forward activation and inactivation rate constants. These effects likely result from multiple sites of isoflurane interaction with the channel. Mutagenesis and structural modeling will be required to test the S4--S5 linker residue S129 and the extracellular P-loop residue S208 as putative anesthetic binding sites mediating effects on activation and the role of the T189 binding site in modulating inactivation. This work provides a biophysical and structural framework to guide further structural studies and facilitate the design of more effective and safer general anesthetics.
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